Scientists Hack Cell Entry to Supercharge Cancer Drugs
A study published in the journal Cell from Hui-Kuan Lin and colleagues could help revive drugs once considered too big to work.
How Duke Research Turned Failure into Hope for Patients with Breast Cancer
A breast cancer drug approved in 2023 that was identified in the lab of Donald McDonnell, PhD, is helping women with late-stage breast cancer.
Shutting Down a ‘Dark Kinase’ May Defeat Treatment-Resistant Cancers
A multi-faceted study from Department of Pharmacology and Cancer Biology researchers shows for the first time that blocking an under-studied enzyme called PKN2 may be the key to stopping aggressive, treatment-resistant cancers.
Slotkin Awarded SOT 2025 Distinguished Neurotoxicologist Award
The Distinguished Neurotoxicologist Award recognizes those "who have made important, high-impact scientific, regulatory, or service contributions" to Neurotoxicology.
Abbie Ireland Receives the Dean’s Award for Research Excellence
The student awardees were selected for their publication record, influence on the research direction of their laboratory, and noteworthy and distinctive contributions to the scientific and academic community.
Discovery of Cancer Cell ‘Factories’ Provides Clues to New Treatments
Research led by Greg Wang, PhD, shows how clusters of cancer cells called NUP98 fusions lead to leukemia. The study was published in the journal in Molecular Cell.
NIH Funding Sustains Scientific Discovery
The Duke Department of Pharmacology and Cancer Biology ranks seventh in the nation in NIH funding, based on grants awarded during the federal fiscal year ending September 30, 2024.
Explainer: Why Universities Need Support for Research Facilities and Administrative Costs
The National Institutes of Health's proposal to cap reimbursement of facilities and administrative (F&A) costs on research grants at 15% would significantly slow or cease scientific and biomedical research at Duke and other research institutions. Here is an explanation of what F&A costs are and why they are such a critical piece of the research endeavor.
Three Questions with: Trudy G. Oliver
Dr. Oliver is focused on understanding the biology of under-studied subtypes of lung cancer, specifically squamous and small cell lung cancer. Her lab investigates mechanisms of tumor development, plasticity, and drug resistance to uncover vulnerabilities that can be therapeutically targeted.
Tsvetanova Receives ASPET Division for Molecular Pharmacology Early Career Award
Nikoleta Tsvetanova, PhD, assistant professor of pharmacology and cancer biology, has been awarded the 2025 Division for Molecular Pharmacology Early Career Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET).